[1]田 倩,曹润怿,王方方,等.CXCL13参与AR促进前列腺癌细胞体内异种移植瘤的生长[J].南京师范大学学报(自然科学版),2018,41(03):70.[doi:10.3969/j.issn.1001-4616.2018.03.012]
　Tian Qian,Cao Runyi,Wang Fangfang,et al.CXCL13 Involved in AR-Mediated Prostate Cancer CellXenograft Tumor Proliferation in vivo[J].Journal of Nanjing Normal University(Natural Science Edition),2018,41(03):70.[doi:10.3969/j.issn.1001-4616.2018.03.012]
点击复制

CXCL13参与AR促进前列腺癌细胞体内异种移植瘤的生长()
分享到：

《南京师范大学学报》（自然科学版）[ISSN:1001-4616/CN:32-1239/N]

卷:
第41卷
期数:
2018年03期
页码:
70
栏目:
·生命科学·
出版日期:
2018-09-30

文章信息/Info

Title:
CXCL13 Involved in AR-Mediated Prostate Cancer CellXenograft Tumor Proliferation in vivo
文章编号:
1001-4616(2018)03-0070-08
作者:
田 倩; 曹润怿; 王方方; 董佳杰; 柯 敏; 卢 山; 刘 平
南京师范大学生命科学学院,江苏省分子与医学生物技术重点实验室,江苏 南京 210023
Author(s):
Tian Qian; Cao Runyi; Wang Fangfang; Dong Jiajie; Ke Min; Lu Shan; Liu Ping
School of Life Sciences,Nanjing Normal University,Jiangsu Key Laboratory for Molecular and Medical Biotechnology,Nanjing 210023,China
关键词:
CXCL13; AR-N; ETS-1; Cyclin B1; 细胞增殖; 前列腺癌
Keywords:
CXCL13; AR-N; ETS-1; Cyclin B1; cell proliferation; prostate cancer
分类号:
Q291
DOI:
10.3969/j.issn.1001-4616.2018.03.012
文献标志码:
A
摘要:
CXCL13作为受AR调节的靶基因之一,参与AR在几株前列腺癌细胞系中的调节功能已有报道. 本研究进一步探讨在裸鼠皮下异种移植瘤模型中CXCL13参与AR对前列腺癌增殖作用的调节,从而验证体外实验的结果. 选用CRPC细胞系CWR22Rv1筛选稳定表达AR-N或CXCL13的细胞株,分为CWR22Rv1(对照)、CWR22Rv1/AR-N、CWR22Rv1/AR-N+siCXCL13、CWR22Rv1/CXCL13 4个组别,裸鼠皮下成瘤30 d后,解剖取瘤. 其中CWR22Rv1/AR-N+siCXCL13组为用CWR22Rv1/AR-N细胞成瘤至100 mm3后,再瘤内注射siCXCL13,每 3 d 一次,共注射3次. 通过形态学观察、测定裸鼠体重和肿瘤大小,发现过表达AR和CXCL13组肿瘤明显大于对照组,而过表达AR再抑制CXCL13组肿瘤明显小于过表达AR组,也比过表达CXCL13组略小,但各组小鼠的体重没有明显变化; Western blot和免疫组织化学结果显示过表达AR-N或CXCL13均能提高ETS-1、Cyclin B1和Snail的表达,而敲减CXCL13后显著削弱AR的调节作用. 表明CXCL13参与AR调节前列腺癌细胞小鼠体内异种移植瘤的生长.
Abstract:
As one of AR-targeted genes,it’s been reported that CXCL13 is involved in AR-mediated regulations of cell growth and proliferation in prostate cancer(PCa)cells. In this study,it’s further demonstrated that CXCL13 promotes prostate cancer cell proliferation in vivo,which is regulated by AR in xenograft tumor models established by CWR22Rv1 cells in nude mice. 20 male nude mice were randomly divided into 4 groups for subcutaneous injections with control CWR22Rv1 cells,CWR22Rv1 cells overexpressing AR,CWR22Rv1 cells knocking down CXCL13(with siCXCL13),or CWR22Rv1 cells overexpressing AR together with knocking down CXCL13. The knock-down of CXCL13 in vivo is performed via intratumoral injection with siCXCL13 every 3 d for 3 times. After tumors grown to 30 d,the differences of tumor growth among groups are analyzed by observing tumor morphology,measuring tumor size and weighting body weight of mice. Furthermore,western blot and immunohistochemistry are used to detect the expression of AR,CXCL13,ETS-1,Cyclin B1 and Snail. All in vivo data here are consistent with the conclusion we obtained in vitro in prostate cancer cell lines,suggesting that CXCL13 is involved in AR-mediated regulations of cell growth and proliferation in PCa cells in vivo.

参考文献/References:

[1] 孙颖浩. 我国前列腺癌的研究现状[J]. 中华泌尿外科杂志,2004,25(2):77-80.
[2]刁鑫伟. 前列腺癌增殖和凋亡与雄激素受体表达的相关性研究[D]. 重庆:第三军医大学,2004.
[3]姜涛,李先承,宋希双,等. 雄激素受体在前列腺癌中表达和意义的探讨[J]. 中国男科学杂志,2005,19(6):29-32.
[4]ANTONARAKIS E S,LU C,WANG H,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer[J]. New England journal of medicine,2014,371(11):1028.
[5]RUPPRECHT T A,KOEDEL U,ANGELE B,et al. Cytokine CXCL13—a possible early CSF marker for neuroborreliosis[J]. Nervenarzt,2006,77(4):470-473.
[6]SINGH S,SINGH R,SHARMA P K,et al. Serum CXCL13 positively correlates with prostatic disease,prostate-specific antigen and mediates prostate cancer cell invasion,integrin clustering and cell adhesion[J]. Cancer letters,2009,283(1):29.
[7]EL HAIBI C P,SHARMA P K,SINGH R,et al. PI3Kp110-,Src-,FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells[J]. Molecular cancer,2010,9(1):85.
[8]WEDEL S A,RADITCHEV I N,JONES J,et al. CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer[J]. Molecular medicine reports,2008,1(2):257.
[9]KAKINUMA T,HWANG S T. Chemokines,chemokine receptors,and cancer metastasis[J]. Journal of leukocyte biology,2006,79(4):639-51.
[10]RODRíGUEZ-FRADE J M,MARTíNEZ-A C,MELLADO M. Chemokine signaling defines novel targets for therapeutic intervention[J]. Mini reviews in medicinal chemistry,2005,5(9):781-789.
[11]VAN DERCAPPELLEN J,VAN DAMME J,STRUYF S. The role of CXC chemokines and their receptors in cancer.[J]. Cancer letters,2008,267(2):226.
[12]RAZIS E,KALOGERAS K T,KOTOULA V,et al. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression[J]. Clinical breast cancer,2012,12(3):183-193.
[13]PANSE J,FRIEDRICHS K,MARX A,et al. Chemokine CXCL13 is overexpressed in the tumor tissue and in the peripheral blood of breast cancer patients[J]. British journal of cancer,2008,99(6):930.
[14]BISWAS S,SENGUPTA S,CHOWDHURY S R,et al. Erratum to:CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis[J]. Breast cancer research and treatment,2014,143(2):265.

备注/Memo

备注/Memo:
收稿日期:2018-02-26.
基金项目:国家自然科学基金(81472415、81272850).
通讯联系人:刘平,博士,教授,研究方向:前列腺癌发展及转移分子基础. E-mail:08201@njnu.edu.cn
更新日期/Last Update: 2018-11-19